What the FDA Approval and Phase 3 Data for Enlicitide Means for Preventive Cardiology
FDA-approved oral PCSK9 inhibitor enlicitide offers once-daily LDL-C lowering, potentially expanding treatment options for high-risk patients unable or unwilling to use injectable therapies.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.